A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study)

Lung Cancer

Volumn 77, Issue 1, 2012, Pages 97-103

  LeCaer, H ^a,h   Greillier, L ^b,g   Corre, R ^c   Jullian, H ^a,p   Crequit, J ^a,i   Falchero, L ^a,q   Dujon, C ^a,o   Berard, H ^d,j   Vergnenegre, A ^e   Chouaid, C ^f   Melloni, B ^e   Barlesi, F ^g   Gimenez, C ^g   Barriere, J R ^h   Auliac, J B ⁱ   Poirier, R ⁱ   Le Treut, J ⁱ   Thomas, P ^k   Muller, P ^k   Grivaux, M ^l   Locher, C ^l   Baud, ^f   Paillotin, D ^m   Lena, H ^c   Delhoume, J Y ⁿ   Simonian, J ^p   David, P ⁱ   Monnet, I ^r   Silvani, J A ^s   Gervais, R ^t   more..

^a Service de Pneumologie   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d Service de Pneumologie   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^h CH   (France)

ⁱ CHU Limoges ^*  (France)

^j Military Teaching Hospital Sainte Anne   (France)

^k CH Gap   (France)

^l CH Meaux   (France)

^m ROUEN UNIVERSITY HOSPITAL   (France)

ⁿ CH   (France)

^o CH Mignot   (France)

^p CH Martigues   (France)

^q CH Villefranche   (France)

^r CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^s CH Bastia   (France)

^t CAEN UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Chemotherapy; Co morbidities; Frail elderly; Lung cancer; Phase II trial

Indexed keywords

ERLOTINIB; GEMCITABINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COGNITION; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG SAFETY; EMOTION; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC ASSESSMENT; HUMAN; KIDNEY DISEASE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUTRITIONAL STATUS; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SOCIOECONOMICS; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GERIATRIC ASSESSMENT; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84861742943     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.02.004     Document Type: Article

References (33)

1. Pallis A.G., Gridelli C., van Meerbeeck J.P., Greillier L., Wedding U., Lacombe D., et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology(SIOG): experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol 2010, 21:692-706.
2. Jatoi A., Hillman S., Stella P., Green E., Adjei A., Nair S., et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005, 23:9113-9119.
3. Gridelli C., Maione P., Illiano A., Piantedosi F.V., Favaretto A., Bearz A., et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES 2P studies. J Clin Oncol 2007, 25:4663-4669.
4. Elderly Lung Cancer Vinorelbine Italian Study Group Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999, 91:66-72.
5. Weiss J., Langer C. Non small-cell lung cancer in the elderly-the legacy of therapeutic neglect. Curr Treat Options Oncol 2009, 10:180-194.
6. Comella P., Frasci G., Carnicelli P., Massidda B., Buzzi F., Filippelli G., et al. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 2004, 91:489-497.
7. Frasci G., Lorusso V., Panza N., Comella P., Nicolella G., Bianco A., et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 2001, 34(Suppl. 4):S65-S69.
8. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003, 95:362-372.
9. Ricci S., Antonuzzo A., Galli L., Tibaldi C., Bertuccelli M., Lopes Pegna A., et al. Gemcitabine monotherapy in elderly patients with advanced non-small celllung cancer: a multicenter phase II study. Lung Cancer 2000, 27:75-80.
10. Wheatley-Price P., Ding K., Seymour L., Clark G.M., Shepherd F.A. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR 21. J Clin Oncol 2008, 26:2350-2357.
11. Jackman D.M., Yeap B.Y., Lindeman N.I., Fidias P., Rabin M.S., Temel J., et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for non-small-cell-lung advanced cancer. J Clin Oncol 2007, 25:760-766.
12. Pal S.K., Katheria V., Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 2010, 60:120-132.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
14. Charlson M., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies development and validation. J Chron Dis 1987, 40:373-383.
15. Spitzer W.O., Dobson A.J., Hall J., Chesterman E., Levi J., Shepherd R., Battista R.N., et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981, 34:585-597.
16. Hollen P.J., Gralla R.J., Kris M.G., Cox C., Belani C.P., Grunberg S.M., et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994, 73:2087-2098.
17. Extermann M., Aapro M., Bernabei R., Cohen H.J., Droz J.P., Lichtman S., Mor V., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005, 55:241-252.
18. Repetto L., Fratino L., Audisio R.A., Venturino A., Gianni W., Vercelli M., et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group Performance Status in elderly patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002, 2:494-502.
19. Luciani A., Bertuzzi C., Ascione G., Di Gennaro E., Bozzoni S., Zonato S., et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol 2010, 28:2046-2050.
20. Soubeyrand P., Bellera C., Heitz D., Cure H., Rousselot H., Albrand G. Validation of the G8 screening tool in geriatric oncology: the ONCODAGE project. J Clin Oncol 2011, 29. [abst 9001].
21. Quoix E., Breton J.L., Ducoloné A., Mennecier B., Depierre A., Lemarié E., et al. First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule. Lung Cancer 2005, 47:405-412.
22. Karampeazis A., Vamvakas L., Agelidou A., Kentepozidis N., Chainis K., Chandrinos V., et al. Docetaxel vs vinorelbine in elderly patients with advanced non-small-cell lung cancer: a Hellenic Oncology Research Group randomized phase III study. Clin Lung Cancer 2011, 12:155-160.
23. Camerini A., Valsuani C., Mazzoni F., Siclari O., Puccetti C., Donati S., et al. Phase II trial of single-agent oral vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status. Ann Oncol 2010, 21:1290-1295.
24. LeCaer H., Barlesi F., Robinet G., Fournel P., Geriniere L., Bombaron P., et al. An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: the GFPC 02-02b study. Lung Cancer 2007, 57:72-78.
25. Hainsworth J.D., Spigel D.R., Farley C., Shipley D.L., Bearden J.D., Gandhi J., et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced non-small cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007, 110:2027-2034.
26. Tibaldi C., Vasile E., Antonuzzo A., Di Marsico R., Fabbri A., Innocenti F., et al. First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study. Br J Cancer 2008, 98:558-563.
27. Gridelli C., Kaukel E., Gregorc V., Migliorino M.R., Muller T.R., Manegold C., et al. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2007, 2:221-229.
28. Quoix E., Zalcman G., Oster J.P., Weestel V., Pichon E., Lavole A., et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with non-small-cell lung cancer: IFCT0501 randomized phase III trial. Lancet 2011, 378:1079-1088.
29. Crinò L., Cappuzzo F., Zatloukal P., Reck M., Pesek M., Thompson J.C., et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008, 26:4253-4259.
30. Stinchcombe T.E., Peterman A.H., Lee C.B., Moore D.T., Beaumont J.L., Bradford D.S., et al. A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer. J Thor Oncol 2011, 6:1569-1577.
31. Provencio M., Camps C., Alberola V., Massutti B., Viñolas N., Isla D., et al. Lung cancer and treatment in elderly patients: The Achilles Study. Lung Cancer 2009, 66:103-106.
32. Gridelli C., Ciardiello F., Feld R., Butts C.A., Gebbia V., Genestreti G., et al. International multicenter randomized phase III study of first-line erlotinib followed by second-line cisplatin plus gemcitabine (CG) versus first line CG followed by second-line erlotinib in advanced non-small-cell lung cancer. The TORCH trial. J Clin Oncol 2010, 28. [abts 7508].
33. Corre R. ESOGIA Trial. [viewed on 30.12.10]. http://clinicaltrials.gov/ct2/show/NCT01257139%3Fterm=corre%26rank=1.